about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Af­ter build­ing pipelines from Glax­o­SmithK­line to Flag­ship, Paul Pe­ter Tak takes the helm at an un­der-the-radar ...

5 years ago
People

#ASH20: Out to shake up CML once again, No­var­tis lays out head-to-head be­tween third-gen Gleevec scion and Pfiz­er ...

5 years ago
R&D

Bare­ly two months af­ter un­veil­ing a new breed of ra­dio­phar­ma­ceu­ti­cals, Rayze­Bio brings to­tal haul to $150M

5 years ago
Financing

Is there room for a new way to drug RNA? ARCH, Fore­site join At­las, The Col­umn Group for $81M bet

5 years ago
Financing
Startups

FDA turns scPhar­ma­ceu­ti­cals and its drug-de­vice for ede­ma away a sec­ond time

5 years ago
FDA+

J&J taps the bis­pe­cif­ic ex­perts at Xen­cor for prostate can­cer dis­cov­ery pact, kick­ing off with $50M up­front

5 years ago
Deals

Af­ter tak­ing on phar­ma M&A, 'pay-for-de­lay' and Gilead­'s remde­sivir pric­ing, Cal­i­for­nia AG tapped to lead HHS — ...

5 years ago
People

Bay­er picks up off-the-shelf CAR-T ap­proach from Atara, spot­light­ing a Memo­r­i­al Sloan Ket­ter­ing break­through

5 years ago
Deals
Cell/Gene Tx

A new RNA part­ner­ship hunts rare epilep­sies; Ab­b­Vie and I-Mab tack­le CD47

5 years ago
News Briefing

J&J guns for quick drug OK in lung can­cer niche, tak­ing the first step chal­leng­ing As­traZeneca in EGFR

5 years ago
FDA+

Covid-19 roundup: Mod­er­na of­fers glimpse at dura­bil­i­ty da­ta; Bribery scan­dals mar Sino­vac's rep­u­ta­tion

5 years ago
Coronavirus

News brief­ing: New senes­cent cell play launch­es with $12M; Jun­shi leads Se­ries C+ in­fu­sion for Chi­nese syn­thet­ic ...

5 years ago
News Briefing

Jaz­z's $1B SCLC drug fails com­bo tri­al, quash­ing hopes of quick full ap­proval. But how much does it mat­ter?

5 years ago
R&D

Covid-19 roundup: In­ovio en­lists plas­mid man­u­fac­tur­er to re­place the one it's in le­gal feud with; Cy­ber­at­tacks ...

5 years ago
Coronavirus

News brief­ing: Ex­elix­is pays $20M to in-li­cense a pre­clin­i­cal ADC for the pipeline; An­oth­er pre­clin­i­cal biotech ...

5 years ago
News Briefing

Ab­b­Vie eyes can­cer, im­munol­o­gy in lat­est pro­tein degra­da­tion pact, hand­ing Fron­tier Med­i­cines $55M up­front

5 years ago
Deals

Covid-19 roundup: CDC votes on who should get vac­cines first; As­traZeneca's In­di­an part­ner won't switch dos­ing ...

5 years ago
Coronavirus

UK grants Pfiz­er, BioN­Tech his­toric first OK for mR­NA vac­cine, ex­pects mil­lions of dos­es by year end

5 years ago
FDA+
Coronavirus

News brief­ing: Mer­ck’s Roger Perl­mut­ter buys his first sol­id tu­mor TriN­KET from Drag­on­fly; Vi­Gen­eron to ex­pand ...

5 years ago
News Briefing

Bridge­Bio grabs a sec­ond pri­or­i­ty re­view for the port­fo­lio — giv­ing Per­cep­tive start­up cause to cel­e­brate

5 years ago
FDA+

Covid-19 roundup: Pfiz­er and Mod­er­na take their vac­cines to the EMA; Chief of Staff Mark Mead­ows calls Hahn to White ...

5 years ago
Coronavirus

Roche shelved these psy­chi­a­try drugs. So its for­mer head of neu­ro cooked up some new plans — and raised $59M for ...

5 years ago
Financing
Startups

Covid-19 roundup: No­vavax de­lays US, Mex­i­co vac­cine tri­al (again); In­dia in­ves­ti­gates re­port­ed side ef­fects in ...

5 years ago
Coronavirus

As­traZeneca CEO So­ri­ot plans new study to test that con­tro­ver­sial 90% ef­fi­ca­cy fig­ure, wait­ing for US da­ta be­fore ...

5 years ago
Coronavirus
First page Previous page 60616263646566 Next page Last page
A service from the Financial Times